 Connection
Brad Constant to Treatment Outcome
This is a "connection" page, showing publications Brad Constant has written about Treatment Outcome.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.112 |
|
|
|
-
Constant BD, Baldassano R, Kirsch J, Mitchel EB, Stein R, Albenberg L. Tofacitinib Salvage Therapy for Children Hospitalized for Corticosteroid- and Biologic-Refractory Ulcerative Colitis. J Pediatr Gastroenterol Nutr. 2022 12 01; 75(6):724-730.
Score: 0.070
-
Larson C, Berinstein JA, Tedesco N, Seidelin JB, Ovesen PD, Uzzan M, Amiot A, Nuzzo A, Laharie D, Constant BD, Albenberg L, El-Hussuna A, Bishu S, Cohen-Mekelburg S, Higgins PDR, Steenholdt C. Postoperative Outcomes in Tofacitinib-Treated Patients With Acute Severe Ulcerative Colitis Undergoing Colectomy. Clin Gastroenterol Hepatol. 2025 Nov; 23(12):2263-2271.e6.
Score: 0.021
-
Mitchel EB, Dolinger MT, Constant B, Wang Z, Guisado D, Gao M, Fusillo S, Baldassano RN, Kelsen J, Dubinsky M, Huang J, Albenberg L. Ustekinumab is safe and effective in pediatric patients with Crohn's disease. J Pediatr Gastroenterol Nutr. 2025 Apr; 80(4):653-663.
Score: 0.021
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|